Medical/Pharmaceuticals
Asieris Presents for the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU
SHANGHAI, Jan. 29, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the first-time ...
2024-01-29 14:05
2288
Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide
THIS PRESS RELEASE CONTAINS INFORMATION THAT NANOFORM IS OBLIGED TO MAKE PUBLIC PURSUANT TO THE EU MARKET ABUSE REGULATION. THE INFORMATION WAS SENT FOR PUBLICATION THROUGH THE AGENCY OF THE CONTACT PERSONS SET OUT BELOW, ONJANUARY 26, 2024, AT 11:20 FINNISH TIME / 10:20 SWEDISH TIME. HELSINKI, ...
2024-01-26 20:08
2267
FDA clears RF Medical's MYGEN™ M-3004 and MYOBLATE™ Radiofrequency Ablation System
SEOUL, South Korea, Dec. 12, 2022 /PRNewswire/ -- RF Medical Co., Ltd. is a
premier Korean-based medical company serving the healthcare industry for almost
two decades. Recently, FDA cleared RF Medical's patented MYGEN™ M-3004
generator and MYOBLATE™ radiofrequency ablation system.
2024-01-26 15:26
1854
AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site
* US$223 million expansion will add biologics capacity to AbbVie manufacturing network * Singapore manufacturing site to grow to more than 500 employees following expansion * Construction will commence immediately with facilities becoming operational in 2026 SINGAPORE, Jan. 26, 2024 /PRNews...
2024-01-26 08:30
6670
Ceva Santé Animale acquires Scout Bio, paving the way for groundbreaking innovations in pet therapeutics
LIBOURNE, France, Jan. 26, 2024 /PRNewswire/ -- Ceva Santé Animale (Ceva), the #5 animal health company present in 110 countries worldwide, announcesthe strategic acquisition of Scout Bio, a pioneer in biotechnology focused on cutting-edge therapies for pets. The move represents a significant lea...
2024-01-26 06:00
4360
First International Shipment of HANSIZHUANG Launched
SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- On January 25, a truck carrying anti-PD-1 mAb Zerpidio® (serplulimab, Chinese trade name: HANSIZHUANG) slowly left Henlius' Songjiang First Plant. These products, bearing Henlius' mission of benefiting patients worldwide with high-quality biopharmaceuticals...
2024-01-25 21:41
3595
Esaote unveils its new brand identity at 2024 Worldwide Sales & Marketing Meeting, Florence
A new logo and the new "Health with Care" payoff, to convey innovation and technology with empathy GENOA, Italy, Jan. 25, 2024 /PRNewswire/ -- Esaote Group, a leading Italian innovator in medical imaging, todayunveiled its new brand identity at the 2024 Worldwide Sales & Marketing Meeting inFlor...
2024-01-25 21:00
3501
First International Shipment of HANSIZHUANG
SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- On January 25, a truck carrying HANSIZHUANG Zerpidio® (anti-PD-1 monoclonal antibody, Chinese trade name: HANSIZHUANG) slowly left Henlius' Songjiang First Plant. These products, bearing Henlius' mission of "benefiting patients worldwide with high-quality ...
2024-01-25 20:45
5668
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World
* Glenmark will be responsible for further developing, registering, and commercializing Envafolimab inIndia, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. * Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additio...
2024-01-25 18:38
2517
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World
* Glenmark will be responsible for further developing, registering, and commercializing Envafolimab inIndia, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. * Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additio...
2024-01-25 18:00
2536
Asieris will Present For the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU
SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the interi...
2024-01-25 16:56
2216
Alphamab Oncology and 3DMedicines Entered into a Licensing Agreement with Glenmark for KN035
SUZHOU, China, Jan. 25, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and 3DMedicines (stock code: 1244.HK) ("Licensors") announced that we entered into a license agreement with Glenmark Specialty S.A. (GSSA), a subsidiary of Glenmark Pharmaceuticals Ltd. (BSE: 532296，NSE: GLENMARK...
2024-01-25 10:40
2777
PS128 Successfully Targets Behavioral and Emotional Challenges in Autism Spectrum Disorder (ASD): Completion of Pivotal Clinical Trial on Preschool Children with ASD
SAN DIEGO, Jan. 25, 2024 /PRNewswire/ -- A recent study published in the
Research in Autism Spectrum Disorders unveils groundbreaking solutions for
neurodevelopmental disorders. This is the first double-blinded, randomized,
placebo-controlledtrial
2024-01-25 10:00
3566
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect
- WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by producing afucosylated antibodies with the ability to increase antibody-dependent cell-mediated cytotoxicity (ADCC), providing diverse bioprocessing solutions for global clients - WuXiaADCC PLU...
2024-01-25 08:30
2640
icotec ag raises $30m in growth financing from MVM Partners
ALTSTAETTEN, Switzerland and EAST HARTFORD, Conn., Jan. 24, 2024 /PRNewswire/ -- icotec ag, the leading company in the field of innovative spinal tumor implants is pleased to announce a significant milestone in its growth journey by establishing a strategic partnership with MVM Partners ("MVM"), ...
2024-01-25 01:45
2564
FDA purchases digiM I2S software for the assessment of product quality attributes
Reviewers and regulatory researchers to use AI image analytics for process-quality correlation WOBURN, Mass., Jan. 24, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration has placed a purchase order (75F40123P00369) committing to an annual subscription of digiM I2S, a fully integrated ima...
2024-01-24 23:37
2019
Wellysis Goes Global with ECG Monitor 'S-Patch', Enters US and Indian Markets
SEOUL, South Korea, Jan. 24, 2024 /PRNewswire/ -- Digital healthcare innovator Wellysis is making waves in the global market with its revolutionary electrocardiogram (ECG) monitoring solution, 'S-Patch,' securing strategic partnerships and distribution deals to propel its entry into the lucrative...
2024-01-24 22:00
2578
WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit
CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements,Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit inBerlin, Germany. Renowned for her pivotal role in mRNA research, Dr.Xiangrong Song, co-founder and CEO o...
2024-01-24 21:32
2064
Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy
The study confirms that Xanamem is a brain-penetrant inhibitor of the tissue cortisol synthesis enzyme, 11β-HSD1, with high levels of target occupancy at doses as low as 5 mg SYDNEY, Jan. 24, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that its human Positron Emission Tom...
2024-01-24 21:30
2394
Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI
* Results showed partial response being confirmed in 7 out of 42 patients * Partial response was observed in 3 out of 8 patients who were previously treated by immunotherapy SEOUL, South Korea, Jan. 24, 2024 /PRNewswire/ -- Genome & Company (KOSDAQ: 314130), a clinical stage biotech leading in...
2024-01-24 21:00
2269
Week's Top Stories
Most Reposted
Sustainable Tourism Impact Fund Expands Investments Across Southeast Asia
[Picked up by 309 media titles]
2026-04-03 11:30
Visa cements global K-pop connection as Worldwide Tour Sponsor for "BTS WORLD TOUR 'ARIRANG'"
[Picked up by 306 media titles]
2026-04-06 10:00
UTP Advances Across Key Disciplines in QS World University Rankings By Subject 2026 - Petroleum Engineering Among World's Top 10
[Picked up by 298 media titles]
2026-04-06 16:46
Marriott Bonvoy Returns as an Official Partner of the Cathay/HSBC Hong Kong Sevens 2026
[Picked up by 290 media titles]
2026-04-02 18:13
OneQode, Hitachi Vantara & Cylix Form Strategic Alliance to Launch Sovereign AI Factory Initiative
[Picked up by 282 media titles]
2026-04-08 08:00
Most Read
LightInTheBox Files 2025 Annual Report on Form 20-F
2026-04-02 20:00
6199
Korea's Supreme Court Upholds Korea Zinc's Voting Restriction, Rebuffing Young Poong's Legal Challenge
2026-04-03 21:00
5626
ECARX Announces Audited 2025 Full-Year Financial Results
2026-04-02 21:06
5510
